Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series
Journal
Clinical Lung Cancer
Year
2025
Conclusion
This report highlights the unmet medical need of patients with advanced EGFR-mutant, MET-altered NSCLC in clinical practice, and supports the clinical benefit of tepotinib plus EGFR-TKIs in this setting, complementing clinical trial evidence.15,16,21 Given the heterogeneity of treatment resistance mechanisms in oncogene-driven advanced NSCLC and resultant challenge for trial enrollment, compassionate use programs may be increasingly important to enable patient access to novel therapies and generate evidence of therapeutic effectiveness.
Resources and Links
Phone Number: +603 2781 4519 / +603 2781 4520
https://www.clinical-lung-cancer.com/article/S1525-7304(25)00043-9/fulltext
Share the Page
|
Information
Consultant Name
Dr Tho Lye Mun
For general questions about clinical trials
Phone Number: +603 2781 4519 / +603 2781 4520
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you:
8, Jalan Bukit Pantai, 59100 Kuala Lumpur, Malaysia
.png?sfvrsn=71934c60_8)
.png?sfvrsn=1370dfbd_9)
